Skip to main content
. 2024 Mar 26;10(7):e28732. doi: 10.1016/j.heliyon.2024.e28732

Table 2.

Baseline characteristics and univariate analysis of patients with PAD.

Variables Total (n = 281) Sarcopenia (n = 116) No sarcopenia (n = 165) P value
Age (years) 73.0 ± 9.26 76.5 ± 8.67 70.6 ± 8.89 <0.001 *
Sex, n (%)
 Male 201 (71.5) 80 (69.0) 121 (73.3)
 Female 80 (28.5) 36 (31.0) 44 (26.7) 0.425
BMI (kg/m2) 22.5 (14.7, 46.3) 20.8 (14.7, 46.3) 23.4 (15.2, 32.5) <0.001 *
Diabetes, n (%)
 No 138 (49.1) 62 (53.4) 76 (46.1)
 Yes 143 (50.9) 54 (46.6) 89 (53.9) 0.223
HBP, n (%)
 No 69 (24.6) 25 (21.6) 44 (26.7)
 Yes 212 (75.4) 91 (78.4) 121 (73.3) 0.327
CHD, n (%)
 No 233 (82.9) 90 (77.6) 143 (86.7)
 Yes 48 (17.1) 26 (22.4) 22 (13.3) 0.049 *
Stroke, n (%)
 No 217 (77.2) 89 (76.7) 128 (77.6)
 Yes 64 (22.8) 27 (23.3) 37 (22.4) 0.867
Smoking, n (%)
 No 233 (82.9) 97 (83.6) 136 (82.4)
 Yes 48 (17.1) 19 (16.4) 29 (17.6) 0.793
Drinking, n (%)
 No 261 (92.9) 109 (94.0) 152 (92.1)
 Yes 20 (7.1) 7 (6.0) 13 (7.9) 0.555
HbA1c (%) 6.80 (4.50, 13.7) 6.75 (4.50, 12.8) 6.80 (4.70, 13.7) 0.502
ALB (g/L) 38.2 ± 5.45 36.3 ± 5.92 39.5 ± 4.65 <0.001 *
ALT (U/L) 15.0 (2.00, 80.0) 14.0 (3.00, 80.0) 16.0 (2.00, 74.0) 0.949
AST (U/L) 19.0 (8.00, 90) 19.0 (9.00, 90.0) 18.0 (8.00, 88.0) 0.137
FBG (mmol/L) 5.82 (2.28, 19.4) 5.35 (2.28, 19.4) 5.93 (2.86, 15.8) 0.754
BUN (mmol/L) 6.30 (2.00, 31.5) 6.65 (2.00, 29.5) 6.20 (2.70, 31.5) 0.535
Scr (μmol/L) 76.2 (36.7, 226) 76.5 (36.7, 226) 76.2 (39.7, 224) 0.542
BUA (μmol/L) 337 ± 109 338 ± 122 337 ± 99.3 0.897
TC (mmol/L) 4.00 (1.99, 10.5) 3.85 (2.14, 10.5) 4.14 (1.99, 8.90) 0.380
TG (mmol/L) 1.28 (0.39, 8.79) 1.20 (0.50, 8.79) 1.34 (0.39, 7.30) 0.242
HDL-C (mmol/L) 1.00 (0.45, 2.21) 1.00 (0.51, 2.07) 1.00 (0.45, 2.21) 0.904
LDL-C (mmol/L) 2.45 (0.75, 7.00) 2.32 (0.75, 5.66) 2.47 (0.98, 7.00) 0.373
WBC ( × 10^9/L) 7.15 (2.23, 24.2) 7.79 (2.67, 24.2) 7.01 (2.23, 16.6) 0.001 *
PLR 146 (27.1, 685) 155 (49.1, 685) 144 (27.1, 604) 0.002 *
Lesion involved site, n (%)
Lliac artery 277 (98.6%) 115 (99.1%) 162 (98.2%) 0.515
Femoropopliteal artery 271 (96.4%) 116 (100%) 155 (93.9%) 0.999
Below knee triple arteries 261 (92.9%) 112 (96.6%) 149 (90.3%) 0.055
Lesion length, n (%)
 Focal 14 (5.0) 1 (0.9) 13 (7.9) Ref.
 Short 57 (20.3) 17 (14.7) 40 (24.2) 0.011 *
 Intermediate 81 (28.8) 30 (25.9) 51 (30.9) 0.004 *
 Long 129 (45.9) 68 (58.6) 61 (37.0) 0.027 *
Severity of luminal stenosis, n (%)
 Mild 24 (8.5) 1 (0.9) 23 (13.9) Ref.
 Moderate 37 (13.2) 8 (6.9) 29 (17.6) 0.001 *
 Severe 96 (34.2) 34 (29.3) 62 (37.6) <0.001 *
 Occluded 124 (44.1) 73 (62.9) 51 (30.9) 0.001 *
TASC II classification, n (%)
 A 18 (6.4) 1 (0.9) 17 (10.3) Ref.
 B 81 (28.8) 29 (25.0) 52 (31.5) 0.004 *
 C 133 (47.3) 59 (50.9) 74 (44.8) 0.033 *
 D 49 (17.4) 27 (23.3) 22 (13.3) 0.199
PACSS classification, n (%)
 Grade 0 2 (0.7) 1 (0.9) 1 (0.6) Ref.
 Grade 1 9 (3.2) 0 (0) 9 (5.5) 0.850
 Grade 2 7 (2.5) 2 (1.7) 5 (3.0) 0.167
 Grade 3 159 (56.6) 54 (46.6) 105 (63.6) 0.999
 Grade 4 104 (37.0) 59 (50.9) 45 (27.3) <0.001 *
PARC classification, n (%)
No calcification 2 (0.7) 1 (0.9) 1 (0.6) Ref.
Focal calcification 17 (6.0) 3 (2.6) 14 (8.5) 0.982
Mild calcification 47 (16.7) 15 (12.9) 32 (19.4) 0.017 *
 Moderate calcification 93 (33.1) 35 (30.2) 58 (35.2) 0.029 *
Severe calcification 122 (43.4) 62 (53.4) 60 (36.4) 0.055
Collateral circulation formation, n (%)
 No 275 (97.9) 112 (96.6) 163 (98.8)
 Yes 6 (2.1) 4 (3.4) 2 (1.2) 0.222

Data are the number of patients and percentage if not specified.

*P < 0.05.

BMI, body mass index; HBP, high blood pressure; CHD, coronary heart disease; WBC, white blood cell count; PLR, platelet-to-lymphocyte ratio; HbA1c, glycated hemoglobin; FBG, fasting blood glucose; ALB, albumin; AST, aspartate aminotransferase; ALT, alanine transaminase; BUN, blood urea nitrogen; Scr, serum creatinine; TC, total cholesterol; TG, triglycerides; HDL-C, high-density lipoprotein cholesterol; LDL-C, low-density lipoprotein cholesterol; BUA, blood uric acid; PACSS, Peripheral Arterial Calcium Scoring System; PARC, Peripheral Academic Research Consortium.